Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. JSP Pharmaceutical Manufacturing (Thailand) PCL's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 1.89%.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, JSP Pharmaceutical Manufacturing (Thailand) PCL's WACC % is 6.10%. JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC % is 4.02% (calculated using TTM income statement data).
JSP Pharmaceutical Manufacturing (Thailand) PCL earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
JSP Pharmaceutical Manufacturing (Thailand) PCL ROC % Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL ROC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a ROC % of 1.89% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC % too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current ROC % is 1.89%. The Consumer Packaged Goods industry median ROC % is 5.19. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 1.89% is 63.6% below this industry median. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC % compare to KHC and GIS?
JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC % of 1.89% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROC % is 5.19. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 1.89% is 63.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Consumer Packaged Goods company?
The median ROC % among Consumer Packaged Goods companies is 5.19, based on 1,951 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current ROC % of 1.89% is 63.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median ROC % is 5.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current ROC % is 1.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.16, compared to a current price of ฿1.78 — trading 43.7% below its estimated fair value. The current ROC % is 1.89% and 63.6% below the Consumer Packaged Goods industry median of 5.19. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current ROC % is 1.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.78 is trading 43.7% below its estimated GF Value™ of ฿3.16.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.
Key valuation signals for BKK:JSP:
ROC %: 1.89%
GF Value™: ฿3.16 vs. price of ฿1.78 (43.7% below fair value)
Industry Position: 63.6% below the Consumer Packaged Goods median
No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
80GF Score
Get the complete analysis for BKK:JSP
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP has been successfully added to your 
